elminda Ltd.
elminda was founded in 2006 with the goal of addressing the unmet needs of people suffering from brain related disorders. Our mission: perfect a technology that would reveal an individual’s unique brain function “signatures” or “fingerprints,” creating objective measurements to bring greater certainty to the diagnosis of brain disorders and injuries, and enable better clinical decision-making around treatment. ElMIndA is lead by a seasoned team of entrepreneurs, engineers, neuroscientists, researchers and medical experts who have spent a decade-plus developing and improving our technology. We are a diverse group with a thirst for knowledge that drives us to create leading-edge technologies.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About Us
Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges.
And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us.
Being unable to accurately measure and compare how a brain functions hinders doctors’ ability to diagnose and treat suspected ailments.. It also slows the substantiation of new therapies. And, just as importantly, it prevents each of us from truly understanding and taking ownership of the health of our body’s most important organ.
The human brain is a highly complex, multilayered organ composed of many billions of neurons organized into highly complex interconnecting neural networks. These networks carry electrical signals responsible for every human function, from memory to emotions and physical movement.
When brain injuries or illnesses occur, disruption of the brain’s electro-chemical networks leads to dysfunction that is difficult to quantify. Traditional imaging modalities such as CT, MRI and PET are providing us with information on brain anatomy, metabolism, and energy consumption but do not shed enough light on functional brain constructs such as memory, attention, pain or depression. Other functional assessment methods – including clinical assessment and neurocognitive tools – do not allow us to quantify how these underlying networks are performing, revealing only clinical effects and symptoms.
BNATM software allows medical professionals to map neural networks and compare individual patient response pattern to a normative group, that’s why BNATM testing aims is to become a vital tool in effectively understanding brain health.